H1650
モノクロナール抗HLAクラスI抗原 マウス宿主抗体
clone W6/32, purified immunoglobulin, buffered aqueous solution
別名:
モノクロナール抗HLAクラスI抗原
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
W6/32, monoclonal
Application:
FACS, IF, IP
Citations:
43
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
W6/32, monoclonal
form
buffered aqueous solution
species reactivity
monkey, human
technique(s)
flow cytometry: 5 μL using 1 × 106 cells, immunoprecipitation (IP): suitable, indirect immunofluorescence: 1:10 using acetone-fixed human tonsil frozen sections.
isotype
IgG2a
UniProt accession no.
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... HLA-A(3105), HLA-B(3106), HLA-C(3107)
General description
Class I proteins are highly polymorphic, in which HLA-B seems to be the most polymorphic gene in the human genome. HLA-A, -B, -C are classical class I proteins and are heterodimers. HLA-A, -B, -C consists of a polymorphic transmembrane α heavy chain and an invariant water-soluble light chain. HLA-B is located on human chromosome 6p21.
The previously assigned protein identifier P01891 has been merged into P04439. Full details can be found on the UniProt database.
The previously assigned protein identifier P01891 has been merged into P04439. Full details can be found on the UniProt database.
Immunogen
ヒト扁桃白血球膜調製物。
Application
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Immunofluorescence (1 paper)
Immunofluorescence (1 paper)
Biochem/physiol Actions
大部分のヒト有核細胞で発現するヒトHLAクラスI抗原を認識します。本抗体は、ヒトHLAクラスＩ分子 (HLA-A,B,C) の44-45 kDaα鎖ポリペプチドに存在する単形性エピト-プと反応します。本抗体は、免疫沈降法、補体依存性細胞障害試験、フロ-サイトメトリ-、免疫組織化学染色 (アセトン固定, 凍結切片, 塗沫細胞) にご使用いただけます。 アフリカ、アジアの類人猿や旧世界猿の細胞に交差反応性を示します。大部分の新世界猿や非霊長類について、細胞との反応性は認められません。本抗体が認識するエピト-プは、通常のホルマリン固定、パラフィン包埋に対し不安定です。
4th Workshop: code no. P1
5th Workshop: code nos. BP166, BP288, BP407, B 005
4th Workshop: code no. P1
5th Workshop: code nos. BP166, BP288, BP407, B 005
HLA class I molecules like HLA-A, -B and −C help in the presentation of endogenous antigen to CD8+ (cluster of differentiation 8) T cells.
Physical form
0.01 M PBS溶液 (pH 7.4, 1%BSA, 15mMアジ化ナトリウム含有)
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
H1650-100TST: + H1650-50TST: + H1650-VAR: + H1650-BULK:
jan
Xi-Wen Jiang et al.
Molecular medicine reports, 20(1), 593-603 (2019-05-23)
Targeted drugs have been widely used in the treatment of patients with lung cancer, particularly for those with non‑small cell lung cancer (NSCLC). Plasma cell‑free DNA is an emerging clinical tool for the detection of epidermal growth factor receptor (EGFR)
Wenjing Du et al.
Oncogenesis, 7(4), 36-36 (2018-04-25)
The transcriptional factor SALL4, an important stem cell regulator, is expressed in hematopoietic stem cells and various malignancies, but its role in EGFR-mutated NSCLCs has not been studied yet. Here, we report that the expression of Sal-like protein 4 (SALL4)
Major histocompatibility complex class II
The Systematic Identification of Organic Compounds, 3-19 (2011)
The human gene map for performance and health-related fitness phenotypes: the 2005 update
Rankinen T, et al.
Med Sci Sports Exerc., 38(11), 1863-1888 (2006)
Kian Kani et al.
Molecular cancer therapeutics, 11(5), 1071-1081 (2012-03-14)
Clinical oncology is hampered by lack of tools to accurately assess a patient's response to pathway-targeted therapies. Serum and tumor cell surface proteins whose abundance, or change in abundance in response to therapy, differentiates patients responding to a therapy from
関連コンテンツ
Datasheet
Datasheet
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）